Published in J Clin Oncol on January 15, 2001
Tumor self-seeding by circulating cancer cells. Cell (2009) 6.66
BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma. J Clin Oncol (2011) 2.87
From genes to drugs: targeted strategies for melanoma. Nat Rev Cancer (2012) 2.46
A list of candidate cancer biomarkers for targeted proteomics. Biomark Insights (2007) 2.39
Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients. Br J Cancer (2003) 2.20
Interleukin-8 is associated with proliferation, migration, angiogenesis and chemosensitivity in vitro and in vivo in colon cancer cell line models. Int J Cancer (2011) 2.01
Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma. Am J Pathol (2002) 1.96
Host CXCR2-dependent regulation of melanoma growth, angiogenesis, and experimental lung metastasis. Cancer Res (2009) 1.93
Chemokines in tumor angiogenesis and metastasis. Cancer Metastasis Rev (2007) 1.63
Transactivation of vascular endothelial growth factor receptor-2 by interleukin-8 (IL-8/CXCL8) is required for IL-8/CXCL8-induced endothelial permeability. Mol Biol Cell (2007) 1.61
Hepatic cytochrome P450 3A drug metabolism is reduced in cancer patients who have an acute-phase response. Br J Cancer (2002) 1.58
β-Blockers and survival among Danish patients with malignant melanoma: a population-based cohort study. Cancer Epidemiol Biomarkers Prev (2011) 1.55
Melanoma: new insights and new therapies. J Invest Dermatol (2012) 1.54
Expression of CXCR1 and CXCR2 receptors in malignant melanoma with different metastatic potential and their role in interleukin-8 (CXCL-8)-mediated modulation of metastatic phenotype. Clin Exp Metastasis (2003) 1.39
CXCR1 and CXCR2 enhances human melanoma tumourigenesis, growth and invasion. Br J Cancer (2009) 1.27
Growth-inhibitory and antiangiogenic activity of the MEK inhibitor PD0325901 in malignant melanoma with or without BRAF mutations. Neoplasia (2009) 1.23
The good and the bad of chemokines/chemokine receptors in melanoma. Pigment Cell Melanoma Res (2009) 1.18
The role of chemokines and their receptors in angiogenesis. Cell Mol Life Sci (2011) 1.15
Use of ß-blockers and mortality following ovarian cancer diagnosis: a population-based cohort study. BMC Cancer (2013) 1.15
A small-molecule inhibitor of the ribonucleolytic activity of human angiogenin that possesses antitumor activity. Proc Natl Acad Sci U S A (2002) 1.13
Quantitative expression of VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 in melanoma tissue microarrays. Hum Pathol (2009) 1.08
Concentration and Preservation of Very Low Abundance Biomarkers in Urine, such as Human Growth Hormone (hGH), by Cibacron Blue F3G-A Loaded Hydrogel Particles. Nano Res (2008) 1.07
Latest advances in chemotherapeutic, targeted, and immune approaches in the treatment of metastatic melanoma. Mayo Clin Proc (2014) 1.06
CXCL8 and its cognate receptors in melanoma progression and metastasis. Future Oncol (2010) 1.02
Potential interaction between CCR1 and its ligand, CCL3, induced by endogenously produced interleukin-1 in human hepatomas. Am J Pathol (2003) 1.00
Diagnostic and prognostic biomarkers in melanoma. J Clin Aesthet Dermatol (2014) 0.98
Expression and prognostic value of circulating angiogenic cytokines in pancreatic cancer. BMC Cancer (2011) 0.98
Validation of a multiplex immunoassay for serum angiogenic factors as biomarkers for aggressive prostate cancer. Clin Chim Acta (2012) 0.98
A phase 2 pilot trial of low-dose, continuous infusion, or "metronomic" paclitaxel and oral celecoxib in patients with metastatic melanoma. Cancer (2010) 0.98
A phase II, randomized, double-blind, placebo-controlled multicenter trial of Endostar in patients with metastatic melanoma. Mol Ther (2013) 0.97
Imiquimod inhibits melanoma development by promoting pDC cytotoxic functions and impeding tumor vascularization. J Invest Dermatol (2014) 0.97
Circulating serologic and molecular biomarkers in malignant melanoma. Mayo Clin Proc (2011) 0.95
Novel biomarkers and therapeutic targets for optimizing the therapeutic management of melanomas. World J Clin Oncol (2012) 0.94
ABCB5 maintains melanoma-initiating cells through a proinflammatory cytokine signaling circuit. Cancer Res (2014) 0.94
A phase 2 trial of bevacizumab and high-dose interferon alpha 2B in metastatic melanoma. J Immunother (2011) 0.93
Combined vaccine+axitinib therapy yields superior antitumor efficacy in a murine melanoma model. Melanoma Res (2012) 0.92
Serologic and immunohistochemical prognostic biomarkers of cutaneous malignancies. Arch Dermatol Res (2007) 0.92
A(2B) and A(3) adenosine receptors modulate vascular endothelial growth factor and interleukin-8 expression in human melanoma cells treated with etoposide and doxorubicin. Neoplasia (2009) 0.91
Phase II study of temozolomide (TMZ) and everolimus (RAD001) therapy for metastatic melanoma: a North Central Cancer Treatment Group study, N0675. Am J Clin Oncol (2014) 0.91
Targeting vascular endothelial growth factor receptor-1 and -3 with cediranib (AZD2171): effects on migration and invasion of gastrointestinal cancer cell lines. Mol Cancer Ther (2009) 0.90
Targeting CXCR1/CXCR2 receptor antagonism in malignant melanoma. Expert Opin Ther Targets (2010) 0.89
Clinicoprognostic implications of increased serum levels of vascular endothelial growth factor and basic fibroblastic growth factor in early B-cell chronic lymphocytic leukaemia. Br J Cancer (2002) 0.89
Clinical utilization of chemokines to combat cancer: the double-edged sword. Expert Rev Vaccines (2007) 0.89
The Roles of Angiogenesis in Malignant Melanoma: Trends in Basic Science Research over the Last 100 Years. ISRN Oncol (2012) 0.88
Targeted agents for the treatment of metastatic melanoma. Onco Targets Ther (2012) 0.88
Enrichment of CD56(dim)KIR + CD57 + highly cytotoxic NK cells in tumour-infiltrated lymph nodes of melanoma patients. Nat Commun (2014) 0.87
Stabilization of HIF-2α induces sVEGFR-1 production from tumor-associated macrophages and decreases tumor growth in a murine melanoma model. J Immunol (2012) 0.86
Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma. Clin Cancer Res (2015) 0.85
Clinical utility of serum interleukin-8 and interferon-alpha in thyroid diseases. J Thyroid Res (2011) 0.85
The role of VEGF in melanoma progression. J Res Med Sci (2012) 0.85
Towards combinatorial targeted therapy in melanoma: from pre-clinical evidence to clinical application (review). Int J Oncol (2014) 0.85
Consequences and utility of the zinc-dependent metalloprotease activity of anthrax lethal toxin. Toxins (Basel) (2010) 0.84
Evaluating biomarkers in melanoma. Front Oncol (2015) 0.83
GNAS1 T393C polymorphism and disease progression in patients with malignant melanoma. Eur J Med Res (2010) 0.83
The association of blood angioregulatory microRNA levels with circulating endothelial cells and angiogenic proteins in patients receiving dacarbazine and interferon. J Transl Med (2012) 0.83
Highly sensitive detection of melanoma based on serum proteomic profiling. J Cancer Res Clin Oncol (2009) 0.83
Cell context-dependent activities of parthenolide in primary and metastatic melanoma cells. Br J Pharmacol (2010) 0.83
Immunostimulatory AdCD40L gene therapy combined with low-dose cyclophosphamide in metastatic melanoma patients. Br J Cancer (2016) 0.82
Gene regulatory and clinical effects of interferon β in patients with metastatic melanoma: a phase II trial. J Interferon Cytokine Res (2011) 0.82
Phase I/II Trial of Imatinib and Bevacizumab in Patients With Advanced Melanoma and Other Advanced Cancers. Oncologist (2015) 0.82
Serum angiogenin in inflammatory bowel disease. Dig Dis Sci (2005) 0.81
Dual VEGF/VEGFR inhibition in advanced solid malignancies: clinical effects and pharmacodynamic biomarkers. Cancer Biol Ther (2014) 0.80
The effect of menopause and hysterectomy on systemic vascular endothelial growth factor in women undergoing surgery for breast cancer. BMC Cancer (2008) 0.80
Erythropoietin is involved in angiogenesis in human primary melanoma. Int J Exp Pathol (2010) 0.79
Axitinib increases the infiltration of immune cells and reduces the suppressive capacity of monocytic MDSCs in an intracranial mouse melanoma model. Oncoimmunology (2015) 0.79
Targeting angiogenesis in melanoma: prospects for the future. Ther Adv Med Oncol (2010) 0.79
Reduction in circulating pro-angiogenic and pro-inflammatory factors is related to improved outcomes in patients with advanced pancreatic cancer treated with gemcitabine and intravenous omega-3 fish oil. HPB (Oxford) (2012) 0.79
Novel delivery system for T-oligo using a nanocomplex formed with an alpha helical peptide for melanoma therapy. Int J Nanomedicine (2013) 0.78
The combination of axitinib followed by paclitaxel/carboplatin yields extended survival in advanced BRAF wild-type melanoma: results of a clinical/correlative prospective phase II clinical trial. Br J Cancer (2015) 0.78
Angiogenin in sera as an independent prognostic factor in gastric cancer. J Cancer Res Clin Oncol (2003) 0.78
Increased shedding of HU177 correlates with worse prognosis in primary melanoma. J Transl Med (2010) 0.78
Etoposide-Bevacizumab a new strategy against human melanoma cells expressing stem-like traits. Oncotarget (2016) 0.77
Serum angiogenin levels predict treatment response in patients with stage IV melanoma. Clin Exp Metastasis (2007) 0.76
ECOG phase II trial of graded-dose peginterferon α-2b in patients with metastatic melanoma overexpressing basic fibroblast growth factor (E2602). Clin Cancer Res (2013) 0.76
Radiation up-regulates the expression of VEGF in a canine oral melanoma cell line. J Vet Sci (2013) 0.76
Anti-vascular endothelial growth factor antibody bevacizumab in conjunction with chemotherapy in metastasising melanoma. J Cancer Res Clin Oncol (2007) 0.76
Clinicopathological characteristics of vascular endothelial growth factor expression in uveal melanoma: A meta-analysis. Mol Clin Oncol (2014) 0.75
Enzyme-linked immunosorbent assay for pharmacological studies targeting hypoxia-inducible factor 1alpha. Clin Diagn Lab Immunol (2005) 0.75
Doppler ultrasound flowmetry predicts 15 year outcome in patients with skin melanoma. Indian J Surg (2012) 0.75
Increases in serum TARC/CCL17 levels are associated with progression-free survival in advanced melanoma patients in response to dendritic cell-based immunotherapy. J Clin Immunol (2009) 0.75
Thrombomodulin modulates cell migration in human melanoma cell lines. Melanoma Res (2014) 0.75
Serum CEACAM1 Elevation Correlates with Melanoma Progression and Failure to Respond to Adoptive Cell Transfer Immunotherapy. J Immunol Res (2015) 0.75
Melanomas prevent endothelial cell death under restrictive culture conditions by signaling through AKT and p38 MAPK/ ERK-1/2 cascades. Oncoimmunology (2016) 0.75
Angiogenesis and melanoma. Cancers (Basel) (2010) 0.75
The Pathophysiological Impact of HLA Class Ia and HLA-G Expression and Regulatory T Cells in Malignant Melanoma: A Review. J Immunol Res (2016) 0.75
Established and Emerging Biomarkers in Cutaneous Malignant Melanoma. Healthcare (Basel) (2014) 0.75
CEACAM1 and MICA as novel serum biomarkers in patients with acute and recurrent pericarditis. Oncotarget (2016) 0.75
Human recombinant RNASET2: A potential anti-cancer drug. Oncoscience (2016) 0.75
Immunohistochemical analysis of angiogenesis by CD34 and mast cells by toluidine blue in different grades of oral squamous cell carcinoma. J Oral Maxillofac Pathol (2016) 0.75
A phase II study of cediranib, an oral VEGF inhibitor, in previously untreated patients with metastatic or recurrent malignant melanoma. Invest New Drugs (2016) 0.75
Interval sentinel lymph nodes in melanoma: a digital pathology analysis of Ki67 expression and microvascular density. Clin Exp Med (2015) 0.75
Targeting Melanoma with Cancer-Killing Viruses. Open Virol J (2017) 0.75
Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol (2000) 9.70
Long-term (6 and 12 months) follow-up of two prospective, randomized, controlled phase III trials of photodynamic therapy with BF-200 ALA and methyl aminolaevulinate for the treatment of actinic keratosis. Br J Dermatol (2013) 2.70
"False-positive" anti-neutrophil cytoplasmic antibodies in HIV infection. Lancet (1990) 1.94
Challenge and promise: roles for clusterin in pathogenesis, progression and therapy of cancer. Cell Death Differ (2006) 1.83
Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a multicentre, randomized, observer-blind phase III study in comparison with a registered methyl-5-aminolaevulinate cream and placebo. Br J Dermatol (2011) 1.75
Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a prospective, randomized, double-blind, placebo-controlled phase III study. Br J Dermatol (2010) 1.65
Increased soluble CD95 (sFas/CD95) serum level correlates with poor prognosis in melanoma patients. Clin Cancer Res (2001) 1.53
Extracellular tyrosinase mRNA within apoptotic bodies is protected from degradation in human serum. Clin Chem (2001) 1.50
Phenotypic and genotypic characteristics of a cell line from a squamous cell carcinoma of human skin. J Natl Cancer Inst (1982) 1.49
Treatment of aquagenic pruritus using recombinant interferon-alpha. Br J Dermatol (1997) 1.43
Preservation of morphological, functional, and karyotypic traits during long-term culture and in vivo passage of two human skin squamous cell carcinomas. Cancer Res (1983) 1.42
Growth and differentiation characteristics of transformed keratinocytes from mouse and human skin in vitro and in vivo. J Invest Dermatol (1983) 1.36
Reduced serum 25-hydroxyvitamin D levels in stage IV melanoma patients. Anticancer Res (2009) 1.29
Detection of a human melanoma-associated antigen, p97, in histological sections of primary human melanomas. Int J Cancer (1982) 1.29
A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma. Melanoma Res (2003) 1.24
Detection of circulating melanoma cells by specific amplification of tyrosinase complementary DNA is not a reliable tumor marker in melanoma patients: a clinical two-center study. J Clin Oncol (1997) 1.20
Present concepts and future outlook: function of peroxisome proliferator-activated receptors (PPARs) for pathogenesis, progression, and therapy of cancer. J Cell Physiol (2007) 1.14
CD7-negative helper T cells accumulate in inflammatory skin lesions. J Invest Dermatol (1994) 1.14
Soluble human leukocyte antigen--G serum level is elevated in melanoma patients and is further increased by interferon-alpha immunotherapy. Cancer (2001) 1.06
Redirecting human CD4+CD25+ regulatory T cells from the peripheral blood with pre-defined target specificity. Gene Ther (2009) 1.03
Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG). Br J Cancer (2001) 1.02
Long-term follow-up of photodynamic therapy with a self-adhesive 5-aminolaevulinic acid patch: 12 months data. Br J Dermatol (2009) 1.01
[The "Stade éphélide" of precancerous melanosis. A comparative clinical, histopathological, and electron microscopical study]. Arch Dermatol Forsch (1970) 1.01
Clusterin and DNA repair: a new function in cancer for a key player in apoptosis and cell cycle control. J Mol Histol (2006) 1.00
Sperm morphology assessment using strict criteria and male fertility under in-vivo conditions of conception. Hum Reprod (1996) 0.99
Effects of industrial noise exposure on distortion product otoacoustic emissions (DPOAEs) and hair cell loss of the cochlea--long term experiments in awake guinea pigs. Hear Res (2000) 0.98
CD4+CD7- leukemic T cells from patients with Sézary syndrome are protected from galectin-1-triggered T cell death. Leukemia (2002) 0.98
Heterogeneity of chemosensitivity of metastatic cutaneous melanoma. Anticancer Drugs (1999) 0.97
Dose-intensified bi-weekly temozolomide in patients with asymptomatic brain metastases from malignant melanoma: a phase II DeCOG/ADO study. Ann Oncol (2006) 0.96
Mutational spectrum of NSDHL in CHILD syndrome. J Med Genet (2005) 0.95
Dermal fibroblasts sustain proliferation of activated T cells via membrane-bound interleukin-15 upon long-term stimulation with tumor necrosis factor-alpha. J Invest Dermatol (2001) 0.95
Optimization of photodynamic therapy with a novel self-adhesive 5-aminolaevulinic acid patch: results of two randomized controlled phase III studies. Br J Dermatol (2009) 0.94
Visfatin/PBEF/Nampt and resistin expressions in circulating blood monocytes are differentially related to obesity and type 2 diabetes in humans. Horm Metab Res (2010) 0.91
Analysis of 1,25-dihydroxyvitamin D(3) receptors (VDR) in basal cell carcinomas. Am J Pathol (1999) 0.91
Assessment of gonadal maturation by evaluation of spermaturia. Arch Dis Child (1990) 0.91
Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG). Ann Oncol (2008) 0.91
VDR microRNA expression and epigenetic silencing of vitamin D signaling in melanoma cells. J Steroid Biochem Mol Biol (2010) 0.90
Clinical relevance of sperm morphology assessment using strict criteria and relationship with sperm-mucus interaction in vivo and in vitro. Fertil Steril (1995) 0.90
Ultraviolet light exposure, pigmentary traits and the development of melanocytic naevi and cutaneous melanoma. A case-control study of the German Central Malignant Melanoma Registry. Acta Derm Venereol (1997) 0.90
Progressive increase of CD7- T cells in human blood lymphocytes with ageing. Clin Exp Immunol (1994) 0.90
CD4(+)CD7(-) T cells compose the dominant T-cell clone in the peripheral blood of patients with Sézary syndrome. J Am Acad Dermatol (2001) 0.89
Malignancies of the uterine corpus and immunoreactivity score of the DNA "mismatch-repair" enzyme human Mut-S-homologon-2. J Histochem Cytochem (1999) 0.89
Modes of binding and internalization of monoclonal antibodies to human melanoma cell lines. Cancer Res (1986) 0.88
Upregulation of C4.4A expression during progression of melanoma. J Invest Dermatol (2001) 0.88
High-dose pulse corticosteroid therapy in the treatment of severe alopecia areata. Dermatology (2001) 0.87
T cells redirected by a CD3ζ chimeric antigen receptor can establish self-antigen-specific tumour protection in the long term. Gene Ther (2012) 0.87
[Origin and nature of fibrillar bodies (author's transl)]. Arch Dermatol Forsch (1973) 0.87
[False-positive results in the detection of anti-LAV/HTLV-III antibodies by enzyme immunoassay]. Hautarzt (1986) 0.86
Detection of tumor-associated circulating mRNA in serum, plasma and blood cells from patients with disseminated malignant melanoma. Oncol Rep (2001) 0.86
Correlation of prekaratin peptides and ultrastructure in epithelial cells of human skin tumors in vivo and in vitro. Anticancer Res (1981) 0.85
Regional administration of lymphokine-activated killer cells can be superior to intravenous application. Cancer (1992) 0.85
[Gastric signet ring cell carcinoma presenting. An erysipelas-like cutaneous metastasis of the abdominal skin]. Hautarzt (2008) 0.85
[Randomised phase III trial of fotemustine versus fotemustine plus whole brain irradiation in cerebral metastases of melanoma]. Cancer Radiother (2003) 0.84
Palliative therapy of melanoma patients with fotemustine. Inverse relationship between tumour load and treatment effectiveness. A multicentre phase II trial of the EORTC-Melanoma Cooperative Group (MCG). Melanoma Res (1995) 0.84
Clinical performance of the Nevisense system in cutaneous melanoma detection: an international, multicentre, prospective and blinded clinical trial on efficacy and safety. Br J Dermatol (2014) 0.84
Melanoma-associated retinopathy: high frequency of subclinical findings in patients with melanoma. Br J Dermatol (2003) 0.84
Expression of CD44 splice variants in human skin and epidermal tumours. Virchows Arch (1996) 0.83
Specific lysis of melanoma cells by receptor grafted T cells is enhanced by anti-idiotypic monoclonal antibodies directed to the scFv domain of the receptor. J Invest Dermatol (1999) 0.83
Localization of melanoma-associated antigen p97 in cultured human melanoma, as visualized by light and electron microscopy. J Invest Dermatol (1983) 0.83
Incidence of antiretinal antibodies in melanoma: screening of 77 serum samples from 51 patients with American Joint Committee on Cancer stage I-IV. Br J Dermatol (2005) 0.83
Interferon-alpha and interleukin-2 in the treatment of metastatic melanoma. Comparison of two phase II trials. Cancer (1993) 0.82
Topical imiquimod eradicates skin metastases of malignant melanoma but fails to prevent rapid lymphogenous metastatic spread. Br J Dermatol (2002) 0.82
CD44 variant isoform expression in a variety of skin-associated autoimmune diseases. Clin Immunol Immunopathol (1998) 0.82
Clusterin (CLU) and melanoma growth: CLU is expressed in malignant melanoma and 1,25-dihydroxyvitamin D3 modulates expression of CLU in melanoma cell lines in vitro. Anticancer Res (2006) 0.82
Division of human helper T cells into two sets on the basis of the induction of anti-tumor cytotoxicity by phorbol ester and calcium ionophore. Eur J Immunol (1988) 0.82
Identification of TIA-1+ and granzyme B+ cytotoxic T cells in lichen sclerosus et atrophicus. Dermatology (2001) 0.82
Expression of 1,25-dihydroxy vitamin D3 receptor in breast carcinoma. J Histochem Cytochem (1998) 0.82
Microbial colonization and sperm--mucus interaction: results in 1000 infertile couples. Hum Reprod (1992) 0.81
Reliability of PCR-based detection of occult tumour cells: lessons from real-time RT-PCR. Melanoma Res (2001) 0.81
Can combined T-cell- and antibody-based immunotherapy outsmart tumor cells? Immunol Today (1998) 0.81
[Deficit of natural killer cells (NK cells) in the peripheral blood of patients with atopic dermatitis]. Hautarzt (1986) 0.81
[Ultrastructure of white leaf-shaped macules in tuberous sclerosis (author's transl)]. Arch Dermatol Forsch (1973) 0.81
Prognostic value of in vitro sperm penetration into hormonally standardized human cervical mucus. Fertil Steril (1989) 0.81
Selective alterations in natural killer cell subsets in patients with atopic dermatitis. Int Arch Allergy Appl Immunol (1990) 0.81
Expression of CD44 variant isoforms in malignant melanoma. Clin Cancer Res (1996) 0.81
In vitro generation of IFN-gamma in relationship to in vivo concentration of IgE and IgG subclasses and Fc epsilon Rl/CD23 positive circulating lymphocytes in patients with severe atopic dermatitis (AD). Acta Derm Venereol Suppl (Stockh) (1989) 0.81
Clear cell sarcoma of tendons and aponeuroses: case presentation with special reference to immunohistochemical findings. Hum Pathol (1989) 0.80
Heterogenous susceptibility to CD95-induced apoptosis in melanoma cells correlates with bcl-2 and bcl-x expression and is sensitive to modulation by interferon-gamma. Int J Cancer (1999) 0.80
Dose comparison of tropisetron (Navoban) 5 mg and 10 mg orally in the prophylaxis of dacarbazine-induced nausea and emesis. Semin Oncol (1994) 0.80
Granuloma annulare perforans in herpes zoster scars. J Am Acad Dermatol (1993) 0.80